Kai Feng

Dr. Kai Feng


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2019 in Journal of Ophthalmology
Verified
Journal Article
Open access
YZYing Zhao
Ying Zhao
KFKai Feng
Kai Feng
RLRuibao Liu
Ruibao Liu
JPJinhua Pan
Jinhua Pan
LZLailin Zhang
Lailin Zhang
XLXuejing Lu
Xuejing Lu
Retinitis pigmentosa (RP) is a group of inherited progressive retinal dystrophies that is present with progressive vision loss, night blindness, visual field reduction, and retinal pigmentation of the fundus. RP is an uncommon but clinically important disease. It is progressive and potentially blinding, and to date, no cure for RP has been identified and clinical interventions to retard disease progression are limited. Because of the nature of this disease, there has been great interest in the development of therapeutic interventions that may prevent its progression or restore the loss of visual function. Studies have indicated a possible role of vitamins and minerals in preventing the progression of RP: vitamin A has been reported to have an important role in the function of retinal photoreceptors; lutein is assumed to play a preventive role in fundus diseases; and docosahexaenoic acid, which is found within photoreceptor cell membranes, may have a functional role in preventing the progression of RP. Therefore, this study aimed to systematically review data from randomized clinical trials (RCTs) evaluating the safety and efficacy of vitamins and mineral supplements for the treatment of RP. We searched through relevant trials in the Cochrane Library, PubMed, Embase, Ovid, AMED, OpenGrey, ISRCTN registry, http://ClinicalTrials.gov, and the WHO ICTRP ranging from the respective dates of foundation to June 18, 2018. We reviewed eight randomized control trials (RCTs) with data for 1231 patients. The results indicated that patients with RP may experience delayed disease progression with vitamin and mineral supplementation. In a broader sense, this review suggests that the future trials on RP patients should consider more vitamins or mineral supplements and other outcome measures from the trials included in this review.

2 March 2023 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
KFKai Feng
Kai Feng
CLChang Liu
Chang Liu
KZKeqing Zhang
Keqing Zhang
JHJing Hao
Jing Hao
Background: Henoch-Schönlein purpura (HSP) is a common form of immunological vasculitis in children. Hemophilia A is a genetic disorder and characterized by spontaneous hemorrhage or prolonged bleeding due to factor VIII deficiency. Both diseases increase the risk of bleeding, but they have different mechanisms. How should we treat patients with both diseases? Case presentation: An 8-year-old male with hemophilia A was diagnosed with HSP while receiving coagulation factor VIII replacement therapy in our hospital. Hematochezia occurred 6 days after the diagnosis of HSP. And he treated with coagulation FVIII, methylprednisolone and hemostatic drugs. Conclusions: There is no causal relationship between hemophilia A and HSP, but both diseases can cause bleeding. This child's hematochezia was caused by HSP, but hemophilia could not be ignored during the treatment. Our case report adds to the present body of knowledge about the treatment of HSP associated hematochezia in a child with hemophilia A.

12 March 2021 in Medicine
Verified
Journal Article
Open access
KFKai Feng
Kai Feng
YZYing Zhao
Ying Zhao
QYQingyang Yu
Qingyang Yu
JDJialin Deng
Jialin Deng
JWJingjing Wu
Jingjing Wu
LLLingjia Mm Liu
Lingjia Mm Liu
Introduction: Autism spectrum disorder (ASD) is a neurodevelopmental disorder with increasing incidence. The externalizing and internalizing problems among children with ASD often persistent and highly impair functioning of both the child and the family. Children with ASD often develop gut-related comorbidities and dysbiosis can have negative effects on not only the gastrointestinal (GI) tract, but also psychological symptoms. Dietary exclusions and probiotic supplements also have been investigated in the management of ASD symptoms. Especially, there is some anecdotal evidence that probiotics supplements are able to alleviate GI symptoms as well as improve behaviors in children with ASD. Method and analysis: This review will report on overall studies that include randomized control trials, randomized cross-over studies and cluster-randomized trials designs that consider curative effect in children with ASD by probiotic supplements. We will search 6 databases: MEDLINE, Embase, Scopus, PubMed, The Cochrane Library, and Web of Science and we will perform a manual search the journal Autism and information of ongoing or unpublished studies. The Mixed Methods Appraisal Tool (MMAT) will be used to assess quality of articles and the Jadad scale will be used to assess for bias. Assessment of publication bias will be performed using funnel plots generated by Comprehensive Meta-Analysis (CMA) 3.0 software. Clarifying the evidence in this area will be important for future research directions when reformulating and promoting the therapeutic regime in the field. Ethics and dissemination: There are no human participants, data, or tissue being directly studied for the purposes of the review; therefore, ethics approval and consent to participate are not applicable. The results of this study will be presented at conferences and published in peer-reviewed journals. Registration and status: PROSPERO 2019 CRD42019132754.

23 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
CLChang Liu
Chang Liu
HYHu Yan
Hu Yan
KFKai Feng
Kai Feng
Background: Henoch Schönlein purpura nephritis (HSPN) with a large amount of proteinuria is a risk factor for poor long-term prognosis. Patients with proteinuria at nephrotic level should be actively treated with glucocorticoids combined with cyclophosphamide. However, there was a lack of research on the influence factors of curative effect. The objective of this study was to evaluate factors affecting curative effect in children with HSPN in proteinuria at nephrotic level treated with glucocorticoids combined with cyclophosphamide. Methods: Demographic factors, clinical characteristics, and laboratory data of children with HSPN with or without proteinuria after glucocorticoid combined with cyclophosphamide pulse were retrospectively analyzed. Univariate and multivariate logistic regression analyses were used to determine the risk factors of curative effect in HSPN with nephrotic proteinuria. Results: A total of 107 children with HSPN in nephrotic proteinuria received their first Cyclophosphamide Pulse as part of this study, which included 63 (58.9%) males and 44 females (41.1%), with a median age of 8 years (range: 3-16 years). According to 24 hours proteinuria after 6th cyclophosphamide pulse, subjects were divided into two groups: those with negative of 24-h urine protein quantification (n=72 cases) and those with positive of 24-h urine protein quantification (n=35 cases). After multivariate logistic regression analysis, 24-h urinary protein exceeded normal level during therapy (OR=8.766; 95% CI; 2.521–30.484; P=0.001), repeated skin purpura during therapy (OR=10.821; 95% CI; 1.678–69.780; P=0.012), macroscopic hematuria during therapy (OR=33.900; 95% CI; 2.201–522.131; P=0.012), history of upper respiratory tract infection during therapy (OR=2.122; 95% CI; 1.152–3.908; P=0.013) and fibrinogen (OR=25.053; 95% CI, 1.354–463.708; P=0.016) were found to be independent risk factors for clinical efficacy of glucocorticoid combined with cyclophosphamide. The area under the ROC (AUC) of the model prediction probability was 0.892, with the Hosmer and Lemeshow goodness-of-fit test (P = 0.433, P > 0.05). Conclusion: These results suggest that during the therapy, 24-h urinary protein exceeded normal level, repeated skin purpura, macroscopic hematuria, history of upper respiratory tract infection and higher fibrinogen should be strictly monitored for children with HSPN. Adequate clinical intervention for these risk factors may improve prognosis.

28 October 2022 in Research Square
Verified
Preprint
Open access
PDF file
HLHui Li
Hui Li
KFKai Feng
Kai Feng
Introduction The aim of this study was to explore the association of different protein diet with the recurrence/recurrent rash of Henoch-Schönlein purpura (HSP) and to analyze the potential risk factors for recurrence of HSP. Methods A total of 72 children with HSP treated in Beijing Children's Hospital from January to June 2021 were collected retrospectively. According to the different protein diets, the children were divided into an animal protein group with 32 children and a plant protein group with 40 children. The clinical data of the children were collected, including general data, times of skin rash recurrence, the incidence of HSP recurrence, and the incidence of renal lesions. The daily protein intake of the children was recorded by questionnaire and followed up for 8 weeks after discharge. Results There were no statistical difference between animal protein group and plant protein group in times of skin rash recurrence, the incidence of HSP recurrence, and the incidence of renal lesions of children (p > 0.05). However, the protein intake of animal protein group was significantly higher than that of plant protein group (p < 0.05), which did not affect the recurrence of HSP (p > 0.05). In addition, respiratory infection at the beginning of the disease was potential risk factors for the recurrence of HSP in children (p < 0.05). Conclusions There is no significant association between animal or plant protein diet and the recurrence of HSP or skin rash. Timely avoidance of infection after cure may help to reduce the recurrence rate of HSP in children.